Ototoxicity in Cancer Patients on Cisplatin Therapy Attending Basrah Oncology Centre: A Cohort Study Ototoxicity in Cancer Patients on Cisplatin Therapy
Main Article Content
Keywords
Hearing loss, Cisplatin, Carboplatin, Basrah, Iraq, PTA
Abstract
Background: Cisplatin is a chemotherapeutic agent that is used extensively for the treatment of a broad spectrum of tumors. However, progressive irreversible side effects of Cisplatin, including ototoxicity, have been reported. Methods: A cohort study was implemented from 1 April to 30 August 2015 to study the association between Cisplatin chemotherapy and sensory-neural hearing loss as the major and most important sign of ototoxicity. The cohort group included cancer patients treated with Cisplatin, while patients on Carboplatin were the control group. Cisplatin and Carboplatin belong to alkylating platinum chemotherapy drugs, which are used to treat various malignant solid tumors. Data collection was done through a questionnaire, including information related to sociodemographic characteristics and current and past medical history. Hearing loss was assessed using pure tone audiometry at the time of starting chemotherapy and one month later. Results: The total number of patients was 50, with male to female ratio 1:1 and a mean age of 49.7±14.7 (range 18–80 years): 27 patients were on Cisplatin with a mean age of 50.3±13.5 and 23 patients were on Carboplatin chemotherapy with a mean age of 51.9±15.1 with no significant difference in age (P=0.695). A highly significant association between Cisplatin use and sensory-neural hearing loss (RR, 5.13; P <0.001) was noted. No significant association was found between hearing loss and sociodemographic characteristics or other clinical conditions. Conclusions: Ototoxicity represents a significant clinical sequel of Cisplatin chemotherapy in patients with cancer. A future study using a larger sample size aiming at the evaluation and prevention of Cisplatin induced ototoxicity is recommended.
References
2. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer. 1998; 77:1355–1362.
3. Piel IJ, Meyer D, Perlia CP, Wolfe VI. Effects of cisdiamminedichloroplatinum(NSC-1 19875) on hearing function in man. Cancer Chemother Rep 1974;58: 871-875.
4. Kaufman A. Dizziness and Balance Disorder: An Interdisciplinary Approval. New York, NY, Kugler, 1993.
5. Musial-Bright L, Fengler R, Henze G, Hernáiz Driever P. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst. 2011;27(3):407-413
6. Stohr W, Langer T, Kremers A. Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System. Oncol Rep. 2004; 12:767–771.
7. Warner G, Burgess A, Patel S, Martinez-Devesa P, Cobridge R (Eds). Otolaryngology and Head and Neck Surgery, 1st Edition, Oxford University Press, China, 2009; pp:288-824.
8. Smith R, Shearer A, Hildebrand M, Camp G. Deafness and Hereditary Hearing Loss Overview, Gene Reviews, University of Washington, Seattle. 2014.
9. Pasha R, Golub JS (Eds). Otolaryngology head & neck Surgery Clinical Reference Guide, 3rd Edition, Plural Publishing, USA, 2011; pp:362.
10. Roland N, McRae R, McCombe A. Key topics in otolaryngology and head and neck surgery, 2nd Edition, Tylor & Francis e-Library, UK, 2005; pp:315.
11. Laurence D, Bennet P, Brown M (Eds). Clinical Pharmacology, 8th Edition, Churchil Livingstone, Singapore, 1997; pp:547-555.
12. Khanderia S, Jordan B, Martin J, Ryan R, Wagle S, Amin S, et al (Eds). British National Formulary (BNF) 66, BMJ Group and Pharmaceutical press, Germany, 2013; pp:575-576.
13. Bokemeyer C, Berger CC, Hartmann JT. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77:1355–1362.
14. Hill G, Morest K, Parham K. Cisplatin-Induced Ototoxicity: Effect of Intratympanic Dexamethasone Injections. Otol Neurotol 2008; 29(7): 1005–1011.
15. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J Assoc Res Otolaryngol 2003; 4:139-147.
16. So H, Kim H, Kim Y. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of proinflammatory cytokines via Nrf2/HO-1. J Assoc Res Otolaryngol, 2008; 9:290-306.
17. Kim HJ, Lee JH, Kim SJ. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010; 30:3933-3946.
18. Rybak L, Husain K, Morris C, Whitworth C, Somani S. Effect of Protective Agents Against Cisplatin Ototoxicity. Am J Otol 2000; 21(4): 513-520.
19. Allen GC, Tiu C, Koike K, Ritchey AK, Kurs-Lasky M, Wax MK. Transient evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol. Head Neck Surg. 1998; 118:584–588.
20. Huang Z, Timerbaev AR, Keppler BK, Hirokawa T. Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. J. Chromatogr. A. 2006; 1106(1-2):75–79.
21. Rademaker-Lakhai J, Crul M, Zuur L, Baas P, Beijnen J, Simis Y, et al. Relationship Between Cisplatin Administration and the Development of Ototoxicity. J Clin Oncol. 2006;24(6):918-924.
22. Brunton L, Lazo J, Parker K. Goodman & Gilmanʼs the pharmacological basis of therapeutics. Eleventh edition. McGraw-Hill companies. 2006; pp:1333-1334.
23. Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, et al. Prospective evaluation of cisplatin- and carboplatin mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett. 2013; 5(1): 311–315.
24. Freilich R, Kraus D, Budnick A, Bayer L, Finlay J. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26(2):95-100.
25. De Lauretis A, De Capua B, Barbieri M, Bellussi L, Passàli D. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or Carboplatin. Scand Audiol. 1999;28(3):139-143.
26. Montaguti M , Brandolini C , Ferri GG , Hatzopoulos S , Prete A , Pession A. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital. 2002; 22(1):14-18.
27. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N et al. Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss. J Pediatr Hematol Oncol. 2004 Oct;26(10):649-655.
28. American Speech-Language-Hearing Association. (1990). Sound field measurement tutorial II-371. Rockville, MD.
29. American National Standards Institute. (2004). Methods for manual pure-tone threshold audiometry (ANSI S3.21-2004). New York.
30. Hildebrand MS, Husein M, Richard JH. Genetic Sensorineural Hearing Loss. Cummings Otolaryngology: Head & Neck Surgery. 5th edition, Mosby inc: An Imprint of Elsevier. 2010: 94-95
31. Murphy MP , Gates GA. Hearing Loss: Does Gender Play a Role? Medscape Women's Health.1997; 2(10):2.
32. Habib OS, Al-Ali JK, Al-Wiswasi MK, Ajeel NAH, Al-Asadi OG, Khalaf AA, Al-Mayah AZM. Cancer in Basrah 2005: preliminary results. Health and health care service in Basrah A set of performance indicators, University of Basrah college of medicine. Basrah. 2011. Chapter nine. pp:103-104.
33. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Kluwer Academic Publishers. Netherlands. 1998.
34. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of Cisplatin and Carboplatin. J Clin Oncol. 1999;17(1):409-422.
35. Rybak L, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. Tohoku J Exp Med. 2009; 219(3):177–186.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.